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Abstract
Heterotopic ossification (HO) is defined as the process by which trabecular bone forms outside of
the skeletal structure, occupying space in soft tissue where it does not normally exist. The current
popular prophylactic treatment modalities include non-steroidal anti-inflammatory drugs (NSAIDs)
and radiation therapy, although the literature remains inconclusive as to which is superior.
Additionally, both treatments can lead to adverse effects to the patient. Recently there have been
several studies attempting to identify new aspects of the etiology of heterotopic bone formation
and introduce new prophylactic modalities with increased efficacy and fewer side effects. For this
review, we selectively retrieved articles from Medline published from 1958–2008 on the
prophylaxis of HO with the aim of assisting readers in quickly grasping the current status of
research and clinical aspects of HO prophylaxis.
Background
Heterotopic ossification (HO) is defined as the process by
which trabecular bone forms outside of the skeletal struc-
ture, occupying space in soft tissue where it does not nor-
mally exist. This misplaced growth occurs between muscle
planes and not within the muscle fibers themselves. Fur-
thermore, though the new bone often abuts existing skel-
etal structure, it does not interfere with the configuration
of the periosteum[1].
The heterotopic ossification of muscles, ligaments and
tendons is a potential complication following trauma,
elective surgery, neurological injury and severe burns[2].
The most common site for the formation of HO is follow-
ing open-reduction internal-fixation (ORIF) for acetabu-
lar fracture, followed by the hip after total hip arthroplasty
(THA)[3,4]. Following THA, the incidence of HO has
been reported as being between 5 and 90%, though only
3 to 7% of patients experience clinically significant HO;
that is, to an extent that the outcome of the surgery is
affected and as designated a grade of III or IV as originally
described by Brooker in reference to the hip joint (Table
1)[5,6]. Reported incidence is lower following primary
total knee arthroplasty (TKA), and has been reported as
between 3.8 and 39% for all Brooker classification grades,
but as one study reported only 1% of patients were symp-
tomatic[5].
This article is meant to serve as a review and an update on
the literature regarding current prophylaxis modalities as
well as treatments under investigation for prevention of
heterotopic ossification. It is our hope that these new
methods will be more effective and with fewer side effects
than their predecessors, allowing far fewer patients to suf-
fer with the debilitating effects of this disease.
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Mechanisms of heterotopic ossification
The etiology of HO can be divided into the three headings
of neurological, genetic and traumatic, with orthopaedic
procedures included in this last group[5]. Though the eti-
ology has been classified, the exact pathophysiology of
HO remains unknown. Several contributory factors have
been suggested. Prostaglandin activity, specifically PGE-2,
as well as hypercalcemia, tissue hypoxia, alterations in
sympathetic nerve activity, prolonged immobilization
and imbalances between parathyroid hormone activity
and calcitonin have all been shown to contribute to HO
formation[7]. These factors help to enable the improper
differentiation of pluripotent mesenchymal stem cells
into osteoblastic precursors[5]. Furthermore, numerous
risk factors have been identified in several studies. Those
studied in association with hip arthroplasty include a his-
tory of HO in the ipsilateral or contralateral hip, posttrau-
matic arthritis, hypertrophic osteoarthritis, rheumatoid
arthritis, ankylosing spondylitis, diffuse idiopathic skele-
tal hyperostosis, osteonecrosis, Paget disease and male
sex[8,9].
It is known that heterotopic ossification is determined by
both systemic factors and by local tissue changes, prima-
rily characterized by inflammation[10], cell death[11],
and upregulation of mineralization growth factors [12-
14]. Both inflammation and cell death can result in local
alterations in pH and matrix that promote the deposition
of calcium in the form of hydroxyapatite crystals. Growth
factors such as BMPs stimulate mineralization and bone
formation via their effects on osteoblast progenitor cells.
Several studies have utilized animal models as a means of
studying the process and prevention of HO. These have
included the use of rabbits, mice, rats, canines, goats and
sheep and have had a significant impact on the study of
HO[2,12-17]. The three most commonly used models are
the rabbit quadriceps model, the rabbit hip model and the
rodent soft tissue model with BMP injection. The rabbit
quadriceps exercise model was developed by Michelsson
et al[14]. One of the animal's legs is immobilized with the
knee in extension using a plastic splint for up to 5 weeks.
Six days a week, a 5 minute session of forceful mobiliza-
tion through the full range of motion is performed. While
Michelsson et al. previously[18] showed that immobiliza-
tion in extension led to degenerative joint changes and
stiffness of the joint that gradually resolved at the end of
the immobilization period, forceful manipulation was
required to result in permanent stiffness of the knee and
development of heterotopic bone in the quadriceps mus-
cles. This model reflects the clinical experience of patients
with early immobilization followed by aggressive physical
therapies[14]. A newer rabbit model involves the reaming
of the femoral medullary canal through a greater tro-
chanter approach, similar to that used in total hip arthro-
plasty [16]. Ischemic injury to the abductor musculature is
induced by occlusion of vessels for 3 minutes during the
procedure. Ischemia, as will be noted later in this manu-
script, has been shown to create free-radicals in skeletal
muscle tissue, causing injury to the tissue and as suggested
by Vanden Bossche et al, may lead to the formation of
HO[1]. This model creates HO in the abductor muscles
which mimics the scenario of HO after total hip arthro-
plasty and acetabular fractures[16]. A third model uses
bone morphogenetic proteins (BMPs) placed in skeletal
muscle to induce HO[2]. These proteins have been dem-
onstrated to induce HO in several previous studies[2,19-
22]. Bone morphogenetic proteins have been shown to be
present during fracture repair; furthermore, inhibition of
chondrogenesis by transforming growth factor-beta has
been shown to be overcome by addition of BMPs in
murine models[23]. Moreover, cell culture models have
demonstrated that BMPs initiate and maintain chondro-
cytes, and even appear to induce differentiation of osteob-
last precursor cells into more mature osteoblast-like
cells[23]. A collagen BMP-4-expressing muscle-derived
stem cell impregnated sponge is inserted into the ham-
string muscles of the rodent to induce HO[2].
The understanding of the process of induction of HO, the
mediators involved (including the origin of involved oste-
oprogenitor cells[16]) and the reasoning behind prophy-
lactic treatments in humans owe their origins to the
observation of the phenomenon in animals. It is the opin-
ion of the authors that the future direction of study will
see animal models continuing to play a dominant role in
advancing the understanding, treatment and prevention
of HO.
Commonly used prophylactic modalities
NSAIDs
The prophylactic effectiveness of indomethacin following
elective lower limb surgery is well-accepted, and has been
shown to help prevent HO, lessen the extent of the devel-
Table 1: Brooker classification of heterotopic ossification [6]
Grade 1 Islands of bone within the soft tissues about the hip
Grade 2 Bone spurs from the pelvis or proximal end of the femur, leaving at least one centimeter between opposing bone surfaces
Grade 3 Bone spurs from the pelvis or proximal end of the femur, reducing the space between opposing bone surfaces to less than one 
centimeter
Grade 4 Apparent bone ankylosis of the hipJournal of Orthopaedic Surgery and Research 2009, 4:12 http://www.josr-online.com/content/4/1/12
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opment of HO and assist in preventing inflammation
associated with acute HO; it is currently part of a widely-
employed prophylaxis protocol[1,5,24-27]. The drug is a
simple and low cost option for prophylaxis. It is impor-
tant to note that several trials have shown that aspirin
does not appear to have the same beneficial effects as
indomethacin[27,28]. The drug works by inhibiting pros-
taglandin-mediated (specifically PGE-2) bone remodeling
and also by directly inhibiting the differentiation of oste-
oprogenitor cells[1,24,25]. A Cochrane Review was con-
ducted in 2004, comprising 16 randomized controlled
trials analyzing the effectiveness of prevention of HO with
the use of NSAIDs[28]. The use of NSAIDs peri-opera-
tively was shown to reduce the risk of developing hetero-
topic bone formation by 59% over placebo. Another
systematic review by Neal, et al. demonstrated a 57%
reduction in the risk of HO when NSAIDs were used as
prophylaxis[27]. The statistical data from this study leads
the authors to predict that for every 100,000 THAs per-
formed in the US each year, perioperative NSAID use has
the potential to prevent anywhere from 10 to 20,000 cases
of heterotopic bone formation. Further, the review
showed no significant difference in the incidence of gas-
tro-intestinal complications between those treated with
NSAIDs and the control. Though both review studies
demonstrated a significant reduction in incidence of HO,
neither addressed clinical outcomes of pain and physical
function among treatments.
However not all trials have seen such a benign side-effect
profile with the use of NSAIDs. Karunakar et al[26]. con-
ducted a randomized, prospective double-blind placebo-
controlled clinical trial on the effect of indomethacin after
the operative treatment of fractures of the acetabulum.
Though as the authors point out the study is lacking in
power, it is significant in that it was determined that there
was no significant difference in the incidence of HO
between the indomethacin and placebo treatment groups.
However, it was noted that one of the indomethacin
patients developed gastrointestinal hemorrhage and one
had a perforated ulcer, while 13 total patients withdrew
from the study due to side effects of the medication, com-
pared with only 1 withdrawing in the placebo treatment.
Others such as Banovac[24] have used misoprostol to aid
in the prevention of gastrointestinal complications.
Another problem with non-selective (ie those actively
inhibiting cyclo-oxygenase 1 and 2, or COX-1 and COX-
2) NSAIDs such as indomethacin is increased periopera-
tive bleeding secondary to inhibition of COX-1, leading to
reduced production of thromboxane A2, which is essen-
tial to platelet aggregation[29]. Fransen et al. followed up
her 2004 Cochrane review with a randomized controlled
trial comparing postoperative pain and physical function
in patients taking either ibuprofen or placebo following
total hip arthroplasty and revision total hip arthroplasty
surgery[30]. Though the overall risk of HO was reduced by
31% (as assessed radiographically) with use of ibuprofen,
the study demonstrated no clinically significant difference
in either pain or physical function 6 to 12 months postop-
eratively. Further, though the risk reduction is impressive,
the raw data (ie number of patients affected) does not sug-
gest as large of an impact on the actual incidence of
Brooker Grade 3 and 4 HO. Among those patients in the
ibuprofen treatment set, 2.5% developed Brooker Grade 3
or 4 HO, whereas the placebo treatment demonstrated an
incidence of 6%[30]. Further, there was a significant
increase in major bleeding complications in the ibuprofen
treatment group, again serving to emphasize untoward
side effects of this treatment modality[30].
One method of circumventing the pitfalls of NSAIDs use
is by employing COX-2 selective NSAIDs, such as meloxi-
cam. Weber et al. have shown that use of this selective
NSAID following total hip arthroplasty was associated
with a 17% reduction in intraoperative and postoperative
(first 24 hours following surgery) blood loss[29]. Further-
more, fewer gastrointestinal side-effects have been noted
as a result of preferential use of COX-2 selective NSAIDs
[31-35]. As noted in additional File 1, more recent studies
have highlighted the both these advantages as well as effi-
cacy comparable to that of traditional, non-selective
NSAIDs[32,34-37]. However, it is notable that the prac-
tice of prescribing COX-2 specific NSAIDs is not without
consequences, as several trials have shown an increased
risk of cardiovascular events associated with their use [38-
40]. Despite this, a few trials have shown either no
increased risk for cardiovascular events when compared to
non-slective NSAID use[41,42] (albeit with lower rates of
GI side effects) or a decreased risk (in the case of
celecoxib[43]) as shown in one study. Due to the current
lack of evidence for safety of routine use of COX-2 selec-
tive NSAIDs as prophylaxis for postoperative HO,
indomethacin remains the gold standard of treatment
when employing NSAIDs therapy[44].
A serious problem with the use of high-dose indometh-
acin and other NSAIDS for HO prophylaxis is that while
new heterotopic bone may be prevented from forming,
the formation of bone for healing the fracture site may
also be impaired. Thus, the large number of reports of
nonunion or malunion as well as poor ligament heal-
ing[5,25,45]. One such study by Burd et al. noted 29%
incidence of nonunion of long bone fractures following
indomethacin prophylaxis, whereas in the radiation arm
the incidence was just 7%[25]. Of note, there were no
instances of acetabular nonunion. In a study by Persson et
al., 142 patients were followed for formation of HO fol-
lowing THA. Of the 11 that underwent a revision proce-
dure secondary to aseptic loosening, 10 belonged to the
indomethacin group[46].Journal of Orthopaedic Surgery and Research 2009, 4:12 http://www.josr-online.com/content/4/1/12
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Radiation Therapy
Studies by Cooley and Goss[47] in 1958 and later those
by Craven and Urist[48] in 1971 demonstrated the effects
of irradiation therapy on bone growth and repair. After
demonstrating the inhibiting influence of the radiation
on bone repair of rat bone and seeing that the effects were
more pronounced when the treatment was initiated closer
to the time of the fracture, the authors hypothesized that
the early osteoprogenitor cells involved in bone repair
were more radiosensitive than the more mature cells seen
later[4]. In 1981, Coventry et al. established the utility of
radiotherapy (RT) as prophylactic treatment for HO by
irradiating the hips of 42 patients who had undergone hip
surgery[49] 48 hips, each designated as high risk for the
formation of HO, were treated with a 20 Gy dose of radi-
ation. Of those treated, 19% developed ectopic bone, not-
ing that patients treated earlier enjoyed lower rates of HO,
though data specifics were not included. Today, RT is used
prophylactically (albeit in much smaller doses) both pre-
and postoperatively for the prevention of HO following
bone fracture or manipulation secondary to trauma or
operative treatment[3,4,50]. Recently, Childs et al. noted
that based on a retrospective cohort study of 263 patients
having experienced traumatic acetabular fracture, HO was
discovered in 5.3% of patients receiving RT, while 60% of
patients who did not receive treatment developed some
degree of ectopic bone[51]. Further, a study by Chao et al.
has demonstrated RT to be capable of preventing HO in
high-risk patients, specifically those in whom a history of
HO exists[52].
Several studies comparing preoperative to postoperative
radiation therapy (RT) were reviewed by Balboni et al. in
a critical review of RT for HO prophylaxis[4]. Studies cited
by the authors suggest that there is not a statistically sig-
nificant difference between employing preoperative (<4
hours preoperatively) or postoperative (<72 hours post-
operatively) RT. In particular the authors cite Gregoritch et
al[50] and Seegenschmiedt et al[53] In Gregoritch's study
122 patients undergoing THA and deemed at a high risk
of HO were treated with either preoperative or postopera-
tive RT. The authors reported no significant difference
among the treatment arms, noting a 28% incidence in the
postoperative treatment and 26% incidence in the preop-
erative treatment (p = 1.0). They calculated a 5% incidence
of clinically significant (Brooker Grade 3 or 4) HO in the
postoperative group and a 2% incidence in the preopera-
tive group (p  =  0.58). In Seegenschmiedt's study, 161
patients were randomized to receive either preoperative or
postoperative RT. Of those treated, 4 (5%) failures were
noted in the postoperative group, compared with 11
(19%) in the preoperative group (p <0.05). However, the
authors noted that the majority of failures in the preoper-
ative group occurred in patients with preexisting Brooker
Grade 3 or 4 HO which had not been removed prior to
treatment. Thus, the authors conclude that there both pre-
and postoperative treatment are equally effective.
Childs et al. had similar results regarding timing of treat-
ment in a study evaluating postoperative RT for HO
prophylaxis following traumatic acetabular fractures[51].
Of 152 patients studied, 58 received radiation within 24
hours of surgery, 41 within 48 hours, 53 within 72 hours,
13 within 4 days and 4 were delayed longer than 4 days.
The authors noted no increase in HO when prophylactic
RT was initiated anywhere from one to four days postop-
eratively.
There are several potential side effects of RT, the most con-
cerning of which is the theoretical effect of carcinogenesis;
however there has yet to be a documented case of a radia-
tion-induced tumor after RT for HO prophylaxis[4]. This
positive outcome is thought to be the effect of both low
doses of radiation as well as an older patient population –
as the latency period for induction of malignancy follow-
ing RT is from 15 to 24 years, it is a possibility that there
are too few patients that survive long enough after treat-
ment for the carcinogenic effects to be realized[4,50].
Therefore, as this treatment option is employed for
younger patients, this concern is worth considering.
Another possible complication of RT (and one that also
plagues indomethacin treatment, as mentioned above) is
the risk of bony nonunion, as has been demonstrated
when trochanteric osteotomy is necessary to remove the
prosthesis during a revision procedure[4,49,54]. Rates of
nonunion range from 12–30% after RT[4], with the high-
est in Lo et al., in which the authors noted that of the 6
patients in whom osteotomy was necessary, 2 developed
a nonunion[54]. In non-irradiated trochanteric osteot-
omy, the rate of nonunion is diminished, occurring only
2–15% of the time[4]. Therefore some authors have advo-
cated the use of shielding to prevent nonunion[9,50].
Finally, radiation dose to the testis is also a concern with
the use of radiation prophylaxis. Animal studies have
shown that reversible oligospermia can be induced with
doses as low as 20 to 70 cGy, and doses of 120 cGy have
been shown to cause permanent azoospermia[4]. The
same study also measured effective testicular dose, show-
ing an average of 25.1 cGy, with a 54% reduction to 11.3
cGy using a testicular shield. For this reason it is recom-
mended that testicular shields always be used during this
treatment and that patients be made aware of the risks
involved with this treatment modality.
Regarding which of these treatments (ie NSAIDs or RT) is
most effective, several trials have found both are effective
means of prophylaxis following arthroplasty and trauma.
They point out that clinical decisions should not be madeJournal of Orthopaedic Surgery and Research 2009, 4:12 http://www.josr-online.com/content/4/1/12
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based on efficacy but rather on factors such as availability,
side effects and cost [55-57]. Strauss et al. (2008) recom-
mend that, when accounting for efficacy and all costs
associated with the use of NSAIDs versus RT (including
patient disability due to HO) for prophylaxis, RT has the
advantage due to a lower incidence of serious side
effects[58]. This attitude is not supported universally,
though several other trials have found an advantage in
efficacy using RT rather than NSAID therapy[9,59]. Kölbl
et al[59] conducted a trial in which 301 patients were ran-
domized to either an NSAID treatment arm, a single 5 Gy
fraction of RT or a 7 Gy fraction of RT. 113 patients were
randomized to the NSAID arm, 95 to the 5 Gy arm and 93
to 7 Gy. The data from the study supported the 7 Gy ther-
apy as being the most effective postoperative treatment
schedule in prevention of clinically significant (Brooker 3
or 4) heterotopic ossification. A study by Pakos et al[9]
had similar results, demonstrating a difference in effective
HO prophylaxis for Brooker grade 3 and 4, albeit only a
1.2% absolute risk reduction.
Combination Therapy
Another option for HO prophylaxis is to combine NSAIDs
and RT. Both Pakos et al[9] and Piatek et al[60] found
combination therapy to be effective, with Pakos' study of
54 patients having only 1 develop clinically significant
HO, though with an overall incidence of 20.4%. This rate
is noticeably higher than that produced by several other
studies, notably Kölbl et al[59], in which the overall rate
of HO formation was 11.6% in the 7 Gy RT arm, with no
instances of Brooker grade 3 or 4 HO. Piatek's[60] study
had only 1 of 24 patients to develop any HO. Very few
studies have examined this treatment modality combina-
tion, and there is still a considerable amount of discussion
regarding whether or not it is worth pursuing[61]. Though
Piatek's study in particular is promising, larger trials must
be implemented to discover the true utility or lack thereof
of a combined prophylaxis protocol.
Methods under investigation
Indomethacin use has led to the development of gastric
ulcers and even gastrointestinal hemorrhage[24,26] in
some patients, as well as bony nonunion[5,25,45] as a
result of its systemic effects. Radiation therapy carries with
it the risks of carcinogenesis[4,50], gonadal dysfunc-
tion[4], and bony nonunion[4,49,54], as with NSAID
therapy. Since the development and use of NSAIDs and
RT for HO prophylaxis, there have been several studies
attempting to pinpoint new aspects of HO etiology and
thus direct the development of new prophylactic modali-
ties with increased efficacy and fewer side effects[1,2,62-
64].
Noggin
Though the exact etiology of HO is not yet fully under-
stood, it is possible that the overexpression of certain
bone morphogenetic proteins (BMPs) may have an influ-
ence on the formation of ectopic bone[2], most notably in
skeletal muscle. BMP-4 in particular has been demon-
strated to be elevated in diseases such as fibrodysplasia
ossificans progressive (FOP), a disease characterized by
the progressive ossification of soft tissue, especially mus-
cle, tendons and ligaments[2,65]. A study by Kan et al[66]
demonstrated experimentally that overexpression of
BMP-4 via a particular gene promoter was able to induce
a FOP-like phenotype.
In addition to the upregulation of BMPs, the downregula-
tion of BMP antagonists such as Noggin, an extracellular
peptide that binds and antagonizes BMPs, may play a role
in the development of heterotopic bone[2,62,66-68].
Hannallah et al[2] have shown that retroviral delivery of
Noggin into HO-predisposed muscle stem cells in mice
(those expressing BMP-4) is able to reduce HO by 53–
99% in a dose-dependent manner. This study also showed
that tissue in which Noggin had been delivered exhibited
an 83% decrease in area of HO following trauma (Achilles
tenotomy). Aspenberg et al[62] also demonstrated the
efficacy of Noggin delivery in prevention of HO, using
both wild-type and engineered strains of the peptide and
Glaser et al[68] demonstrated that direct delivery of Nog-
gin as well as systemic delivery via adenovirus vector was
effective in blocking BMP-4-induced heterotopic ossifica-
tion. A unique study performed by Weber et al. utilized
mutant forms of BMPs that worked in a similar way to
BMP antagonists (like Noggin), but even more effec-
tively[29].
Current research suggests that local and some forms of
systemic delivery of Noggin is effective in combating for-
mation of heterotopic bone in animal models. Our hope
is that Noggin will prove capable of doing the same in
humans, particularly at surgical sites, in light of the high
rates of heterotopic bone formation following procedures
such as hip and knee arthroplasty.
Pulsed Electromagnetic Fields (PEMF)
Based on the assumption that local hypoxia has a role in
the development of HO[69,70], a study by Kociæ et al[64]
has suggested that the use of pulsed electromagnetic fields
(PEMF) could prevent HO by increasing the rate of circu-
lation and oxygenation of soft tissue surrounding a trau-
matic or surgical site. Group A consisted of 131 hips in
117 patients that were administered PEMF treatments
starting 3 days postoperatively and interferential current
starting approximately 14 days postoperatively. Group B
also contained 131 hips in 117 patients, but these patients
were treated with PEMF and interferential current, bothJournal of Orthopaedic Surgery and Research 2009, 4:12 http://www.josr-online.com/content/4/1/12
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starting 14 days postoperatively, as well as kinesitherapy.
Group C consisted of 79 hips in 66 patients who had only
kinesitherapy during postoperative rehabilitation. Group
A had an overall HO incidence of 16.7%, Group B 43.5%,
and Group C 50.6%. (Group A vs. B and vs. C both p
<0.05) Brooker grade 3 and 4 was evident in none of the
Group A patients, in 6.1% of Group B patients and in
26.6% of Group C patients.
Free Radical Scavengers
Oxidative stress occurs when the production of Reactive
Oxygen Species (also referred to as free radicals) are cre-
ated at a faster rate than that at which they are elimi-
nated[1,71]. Large quantities of free radicals are produced
both as a result of the ischemia/reperfusion syndrome and
the so-called disuse phenomenon. The ischemia/reper-
fusion syndrome is a result of isometric muscle contrac-
tions (secondary to muscle hypertonia and contractures)
effectively occluding the muscle's arterial supply and
inducing a state of ischemia. Patients may be started on an
exercise regimen to aid in reperfusion of the tissue, simul-
taneously causing free radical generation[1].
Vanden Bossche describes well the disuse phenomenon.
Muscle atrophy occurs largely as a result not of degrada-
tion of existing proteins, but of the decrease in protein
synthesis, weakening repair mechanisms[1,71]. However,
a reduction in antioxidants available to the tissue also
plays a role, complicated by the release of myoglobin-
derived iron in muscle, which is able to catalyze oxidative
processes responsible for further protein damage[1].
Moreover, the metabolic rate of the muscle involved is
also a consideration, with higher metabolism being asso-
ciated with a higher rate of production of free radicals, and
thus increased tissue damage[1,72]. Knowing that hetero-
topic bone formation is noted to be present following
both of these conditions, Vanden Bossche et al[1] indi-
rectly links the production and action of free radicals to
the process of heterotopic ossification. Drawing on the
theory of the involvement of hypoxia in the pathophysi-
ology of HO, the study examined the use of allopurinol
and N-acetylcysteine (A/A) as free radical scavengers to
prevent ectopic bone formation. Using a rabbit model,
they used 10 animals each in 4 different treatments: pla-
cebo, indomethacin, A/A free radical scavengers, or a com-
bination of free radical scavengers and indomethacin.
They immobilized the left hind leg of each animal to
induce HO. This study demonstrated a significant differ-
ence (p <0.05) between the efficacy of indomethacin and
the increased efficacy of A/A on prevention of HO, as well
as a statistical difference between the A/A and placebo
group. However, no statistical significance was noted
between the indomethacin and placebo groups. Also of
note was that there was not significant difference in effi-
cacy between the A/A group and the combination A/A,
indomethacin group.
Conclusion
Though radiation therapy and NSAIDs remain the most
widely used therapeutic modalities in the setting of post-
surgical heterotopic ossification prophylaxis, it is evident
that they bring with them many hazards and shortcom-
ings. While they represent comparatively cheap and easily
administered treatments, they are plagued with the pro-
pensity to cause bony nonunion, gastrointestinal distur-
bances, and in the case of radiation therapy,
carcinogenesis. Though proponents of COX-2 selective
NSAIDs have sought to correct many of these ills, there is
as of yet not enough evidence of their safety for the
authors to recommend their adoption without reserva-
tion. Noggin (a bone morphogenetic protein inhibitor),
pulsed electromagnetic fields (PEMF), and free radical
scavengers in the form of allopurinol and N-acetylcysteine
are three new methods being evaluated to take the place
of radiation and NSAID therapy as the predominant
method of prophylaxis. While research into alternative
prophylactic modalities is currently in its infancy, the
three mentioned here have thus far shown promise for
fewer associated side effects and better control of hetero-
topic bone formation. It is the hope of the authors that
these modalities will be further developed and made
available for routine use, leading to fewer post-surgical
complications and better outcomes overall.
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